
Christopher Rushton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/625434/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 190-201.	0.8	257
2	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood, 2019, 134, 802-813.	0.6	96
3	The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood, 2019, 134, 1528-1532.	0.6	82
4	Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Advances, 2020, 4, 2886-2898.	2.5	59
5	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nature Medicine, 2020, 26, 577-588.	15.2	46
6	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood, 2020, 136, 572-584.	0.6	44
7	Characterization of DLBCL with a PMBL gene expression signature. Blood, 2021, 138, 136-148.	0.6	19
8	Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. Cell Reports, 2021, 37, 109817.	2.9	14
9	Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries. Methods in Molecular Biology, 2019, 1956, 383-435.	0.4	9
10	Prognostic significance of <i>FCGR2B</i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. Blood Advances, 2021, 5, 2945-2957.	2.5	7
11	CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas. Blood, 2019, 134, 1608-1608.	0.6	5
12	PRPS-ST: A Protocol-Agnostic Self-training Method for Gene Expression–Based Classification of Blood Cancers. Blood Cancer Discovery, 2020, 1, 244-257.	2.6	4
13	Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP. Blood, 2019, 134, 921-921.	0.6	2
14	The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 8-9.	0.6	1
15	Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 31-31.	0.6	1
16	Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma. Blood, 2018, 132, 4610-4610.	0.6	0
17	Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma. Blood, 2019, 134, 1478-1478.	0.6	0
18	NFKBIZ3′ UTR Mutations Confer Selective Growth Advantage and Activate Genes with Therapeutic Implications in Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 296-296.	0.6	0